Wolverine Trading’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-18,100
| Closed | -$55.4K | – | 6102 |
|
|
2024
Q4 | $55.4K | Buy |
18,100
+1,900
| +12% | +$8.28K | ﹤0.01% | 4961 |
|
|
2024
Q3 | $86.8K | Sell |
16,200
-33,100
| -67% | -$164K | ﹤0.01% | 4395 |
|
|
2024
Q2 | $127K | Buy |
49,300
+2,700
| +6% | +$9.22K | ﹤0.01% | 4004 |
|
|
2024
Q1 | $229K | Buy |
46,600
+30,800
| +195% | +$182K | ﹤0.01% | 3644 |
|
|
2023
Q4 | $139K | Sell |
15,800
-1,300
| -8% | -$10.7K | ﹤0.01% | 4013 |
|
|
2023
Q3 | $196K | Sell |
17,100
-10,700
| -38% | -$206K | ﹤0.01% | 3752 |
|
|
2023
Q2 | $687K | Sell |
27,800
-43,400
| -61% | -$1.35M | ﹤0.01% | 2331 |
|
|
2023
Q1 | $2.22M | Buy |
71,200
+37,600
| +112% | +$1.17M | ﹤0.01% | 1306 |
|
|
2022
Q4 | $620K | Sell |
33,600
-24,200
| -42% | -$554K | ﹤0.01% | 2189 |
|
|
2022
Q3 | $1.48M | Buy |
57,800
+37,000
| +178% | +$751K | ﹤0.01% | 1645 |
|
|
2022
Q2 | $296K | Buy |
+20,800
| New | +$320K | ﹤0.01% | 3088 |
|
|
2022
Q1 | – | Sell |
-19,500
| Closed | -$322K | – | 6675 |
|
|
2021
Q4 | $322K | Sell |
19,500
-6,300
| -24% | -$105K | ﹤0.01% | 4049 |
|
|
2021
Q3 | $715K | Buy |
+25,800
| New | +$736K | ﹤0.01% | 3445 |
|
|
2021
Q2 | – | Sell |
-15,200
| Closed | -$423K | – | 6882 |
|
|
2021
Q1 | $423K | Buy |
+15,200
| New | +$420K | ﹤0.01% | 3960 |
|
|
2020
Q4 | – | Sell |
-18,300
| Closed | -$470K | – | 5617 |
|
|
2020
Q3 | $470K | Sell |
18,300
-1,200
| -6% | -$31.5K | ﹤0.01% | 2890 |
|
|
2020
Q2 | $499K | Buy |
19,500
+9,500
| +95% | +$188K | ﹤0.01% | 2724 |
|
|
2020
Q1 | $154K | Sell |
10,000
-5,900
| -37% | -$122K | ﹤0.01% | 3812 |
|
|
2019
Q4 | $256K | Buy |
15,900
+1,300
| +9% | +$20.2K | ﹤0.01% | 3786 |
|
|
2019
Q3 | $201K | Buy |
+14,600
| New | +$179K | ﹤0.01% | 3585 |
|
|
2019
Q2 | – | Sell |
-11,700
| Closed | -$184K | – | 5268 |
|
|
2019
Q1 | $184K | Buy |
11,700
+1,500
| +15% | +$26K | ﹤0.01% | 3887 |
|
|
2018
Q4 | $198K | Sell |
10,200
-3,000
| -23% | -$66.1K | ﹤0.01% | 3708 |
|
|
2018
Q3 | $328K | Sell |
13,200
-8,500
| -39% | -$231K | ﹤0.01% | 3641 |
|
|
2018
Q2 | $668K | Hold |
21,700
| – | – | ﹤0.01% | 2710 |
|
|
2018
Q1 | $668K | Sell |
21,700
-10,800
| -33% | -$347K | ﹤0.01% | 2710 |
|
|
2017
Q4 | $1.16M | Buy |
+32,500
| New | +$933K | ﹤0.01% | 2053 |
|
|
2017
Q3 | – | Sell |
-8,700
| Closed | -$228K | – | 5183 |
|
|
2017
Q2 | $228K | Sell |
8,700
-5,300
| -38% | -$118K | ﹤0.01% | 3431 |
|
|
2017
Q1 | $283K | Sell |
14,000
-2,900
| -17% | -$59.6K | ﹤0.01% | 3094 |
|
|
2016
Q4 | $350K | Buy |
+16,900
| New | +$283K | ﹤0.01% | 3072 |
|
Other funds holding RVNC
Wolverine Trading's RVNC Position: Q2 2024 in Review
Wolverine Trading sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2024, closing a stake of 13,931 shares — an estimated $47.6K sold.
Wolverine Trading first reported a position in RVNC in Q4 2017 and held it in 10 quarters. The position peaked at $692K in Q1 2023. 173 funds tracked by Wall St. Rank hold RVNC as of Q2 2024.
- Wolverine Trading reported no remaining Revance Therapeutics, Inc. position as of Q2 2024 after selling out during the quarter.
- Wolverine Trading sold 13,931 Revance Therapeutics, Inc. shares in Q2 2024, an estimated $47.6K.
- Wolverine Trading first reported a position in Revance Therapeutics, Inc. in Q4 2017 and held it in 10 quarters.
- Wolverine Trading's Revance Therapeutics, Inc. position peaked at $692K in Q1 2023.
- 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2024.
Based on Wolverine Trading's 13F filing for Q2 2024, filed 14 Aug 2024.